- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Dr. Smith's Diaper Rash Ointment
- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
INDIANAPOLIS — Drug maker Eli Lilly will present data from more than 30 studies at the American Society of Clinical Oncology’s annual meeting in Chicago next month, the company said Monday.
Studies will include “PARAMOUNT,” a late-stage clinical trial investigating the drug Alimta (pemetrexed) in patients with advanced non-squamous non-small cell lung cancer, as well as studies on Gemzar (gemcitabine) and Erbitux (cetuximab) with partner companies Bristol-Myers Squibb and Merck KGaA.
“Lilly Oncology is committed to exploring innovations that improve outcomes for all people living with cancer,” Lilly Oncology VP product development and regulatory affairs Richard Gaynor said. “We believe that data from PARAMOUNT, and our other studies at ASCO, demonstrate Lilly’s focus on tailored therapies and commitment to addressing unmet needs in cancer care.”